Partial response observed in a patient with tumor stage IVB CTCL. This patient received 6 prior therapies, including total skin electron beam radiation therapy; cyclophosphamide, vincristine, and prednisolone; denileukin diftitox; and bexarotene. This patient was treated with vorinostat 400 mg every day at the time the response was observed. The CTCL lesions were assessed at baseline and visits at week 8 and week 24.